We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
- Authors
Preziosa, Paolo; Rocca, Maria A.; Nozzolillo, Agostino; Moiola, Lucia; Filippi, Massimo
- Abstract
Dear Sirs, Cladribine is a purine nucleoside analog that inhibits DNA synthesis and repair in highly dividing cells inducing B- and T-cell apoptosis [[1]]. Through a selective but transient depletion of these lymphocyte subsets [[1], [5]], cladribine significantly reduces disease activity and disability progression in relapsing-remitting multiple sclerosis (RRMS) patients [[2]-[4]].
- Subjects
COVID-19; PATIENTS' attitudes; MULTIPLE sclerosis; DISEASE relapse; COVID-19 pandemic
- Publication
Journal of Neurology, 2021, Vol 268, Issue 8, p2697
- ISSN
0340-5354
- Publication type
Letter
- DOI
10.1007/s00415-020-10309-4